This study explores navicixizumab (an experimental cancer medicine) used alone or with other cancer drugs in adults with certain advanced cancers. Cancer types in the study include colon or rectum (CRC), stomach or gastroesophageal junction (GEJ) cancer, triple-negative breast cancer (TNBC), and specific ovarian cancers. After tests, eligible patients will receive treatment in 4-week cycles. Their heart health will be monitored using echocardiograms (a heart scan) and regular blood pressure checks. Tumor progress will be tracked using CT scans (detailed body scans). Participants can stay in the study as long as they benefit from the treatment and do not have severe side effects. If participants drop out, they will still have regular follow-up visits or calls.

• Expect to attend regular study visits and undergo tests.
• The study offers treatment in 4-week cycles.
• Participants may continue as long as they benefit and tolerate the treatment.

To join, you should be 18 or older, have the specific cancers listed, and meet other health requirements. It's essential not to have certain health issues like severe heart problems or uncontrolled high blood pressure.